Does the media refer more to OVID or PGEN?

In the previous week, Ovid Therapeutics had 5 more articles in the media than Precigen. MarketBeat recorded 8 mentions for Ovid Therapeutics and 3 mentions for Precigen. Precigen's average media sentiment score of 1.18 beat Ovid Therapeutics' score of 0.26 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OVID or SNDX?

In the previous week, Ovid Therapeutics had 3 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 8 mentions for Ovid Therapeutics and 5 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Ovid Therapeutics' score of 0.26 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OVID or BCAX?

In the previous week, Bicara Therapeutics had 4 more articles in the media than Ovid Therapeutics. MarketBeat recorded 12 mentions for Bicara Therapeutics and 8 mentions for Ovid Therapeutics. Bicara Therapeutics' average media sentiment score of 0.58 beat Ovid Therapeutics' score of 0.26 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OVID or SION?

In the previous week, Ovid Therapeutics had 1 more articles in the media than Sionna Therapeutics. MarketBeat recorded 8 mentions for Ovid Therapeutics and 7 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.54 beat Ovid Therapeutics' score of 0.26 indicating that Sionna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Sionna Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ovid Therapeutics (OVID) Competitors

$2.43 -0.09 (-3.57%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$2.42 -0.01 (-0.41%)

As of 07/13/2026 07:55 PM Eastern

Compare

OVID vs. LKFT, PGEN, SNDX, BCAX, and SION

Should you buy Ovid Therapeutics stock or one of its competitors? MarketBeat compares Ovid Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ovid Therapeutics include Lakefront Biotherapeutics American Depositary Shares (LKFT), Precigen (PGEN), Syndax Pharmaceuticals (SNDX), Bicara Therapeutics (BCAX), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry.

How does Ovid Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Ovid Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.56	$363.05M	-$1.41	N/A
Ovid Therapeutics	$7.25M	62.56	-$17.41M	-$0.29	N/A

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Ovid Therapeutics had 3 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 8 mentions for Ovid Therapeutics and 5 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.75 beat Ovid Therapeutics' score of 0.26 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ovid Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $34.33, suggesting a potential upside of 15.21%. Ovid Therapeutics has a consensus target price of $5.13, suggesting a potential upside of 110.91%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

Summary

Ovid Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 16 factors compared between the two stocks.

How does Ovid Therapeutics compare to Precigen?

Ovid Therapeutics (NASDAQ:OVID) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Ovid Therapeutics has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market. Comparatively, Precigen has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Ovid Therapeutics has higher earnings, but lower revenue than Precigen. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	62.56	-$17.41M	-$0.29	N/A
Precigen	$9.68M	190.41	-$250.64M	-$1.18	N/A

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Ovid Therapeutics had 5 more articles in the media than Precigen. MarketBeat recorded 8 mentions for Ovid Therapeutics and 3 mentions for Precigen. Precigen's average media sentiment score of 1.18 beat Ovid Therapeutics' score of 0.26 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ovid Therapeutics has a net margin of -240.11% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Precigen	-646.99%	717.50%	58.48%

Ovid Therapeutics currently has a consensus target price of $5.13, suggesting a potential upside of 110.91%. Precigen has a consensus target price of $12.50, suggesting a potential upside of 141.78%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Precigen beats Ovid Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to Syndax Pharmaceuticals?

Ovid Therapeutics (NASDAQ:OVID) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Ovid Therapeutics had 3 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 8 mentions for Ovid Therapeutics and 5 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Ovid Therapeutics' score of 0.26 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals has a net margin of -111.88% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -22.51% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

Ovid Therapeutics has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Ovid Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	62.56	-$17.41M	-$0.29	N/A
Syndax Pharmaceuticals	$172.35M	11.77	-$285.42M	-$2.79	N/A

72.2% of Ovid Therapeutics shares are owned by institutional investors. 7.0% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ovid Therapeutics currently has a consensus price target of $5.13, indicating a potential upside of 110.91%. Syndax Pharmaceuticals has a consensus price target of $42.55, indicating a potential upside of 85.87%. Given Ovid Therapeutics' higher possible upside, analysts plainly believe Ovid Therapeutics is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Ovid Therapeutics beats Syndax Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Ovid Therapeutics compare to Bicara Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Bicara Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -22.51% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Ovid Therapeutics currently has a consensus target price of $5.13, indicating a potential upside of 110.91%. Bicara Therapeutics has a consensus target price of $30.27, indicating a potential upside of 7.54%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ovid Therapeutics is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

72.2% of Ovid Therapeutics shares are owned by institutional investors. 7.0% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ovid Therapeutics has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.81, meaning that its stock price is 181% less volatile than the broader market.

Ovid Therapeutics has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	62.56	-$17.41M	-$0.29	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

In the previous week, Bicara Therapeutics had 4 more articles in the media than Ovid Therapeutics. MarketBeat recorded 12 mentions for Bicara Therapeutics and 8 mentions for Ovid Therapeutics. Bicara Therapeutics' average media sentiment score of 0.58 beat Ovid Therapeutics' score of 0.26 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicara Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ovid Therapeutics beats Bicara Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Ovid Therapeutics compare to Sionna Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and Sionna Therapeutics (NASDAQ:SION) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

In the previous week, Ovid Therapeutics had 1 more articles in the media than Sionna Therapeutics. MarketBeat recorded 8 mentions for Ovid Therapeutics and 7 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.54 beat Ovid Therapeutics' score of 0.26 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sionna Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

72.2% of Ovid Therapeutics shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ovid Therapeutics has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	62.56	-$17.41M	-$0.29	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

Sionna Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -22.51% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Sionna Therapeutics	N/A	-27.31%	-25.88%

Ovid Therapeutics has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

Ovid Therapeutics currently has a consensus target price of $5.13, indicating a potential upside of 110.91%. Sionna Therapeutics has a consensus target price of $53.22, indicating a potential upside of 21.10%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Ovid Therapeutics is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

Summary

Ovid Therapeutics beats Sionna Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Ovid Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OVID vs. The Competition

Export

Metric	Ovid Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$470.33M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-8.38	20.85	27.11	24.26
Price / Sales	62.56	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	2.43	8.49	10.75	6.29
Net Income	-$17.41M	$23.83M	$3.58B	$330.66M
7 Day Performance	-11.96%	-3.56%	-2.06%	-1.32%
1 Month Performance	5.65%	6.31%	3.32%	-0.64%
1 Year Performance	512.24%	48.30%	26.36%	19.08%

Ovid Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OVID Ovid Therapeutics	2.6877 of 5 stars	$2.43 -3.6%	$5.13 +110.9%	+500.0%	$470.33M	$7.25M	N/A	60	Short Interest Increase Gap Down
LKFT Lakefront Biotherapeutics American Depositary Shares	1.746 of 5 stars	$30.78 +1.4%	$36.50 +18.6%	-1.7%	$2.03B	$1.26B	N/A	1,310
PGEN Precigen	3.1573 of 5 stars	$5.69 +1.6%	$12.50 +119.8%	+182.5%	$2.03B	$9.68M	N/A	190	Positive News
SNDX Syndax Pharmaceuticals	2.6728 of 5 stars	$22.66 +2.6%	$42.55 +87.8%	+138.7%	$2.01B	$172.35M	N/A	110
BCAX Bicara Therapeutics	1.7563 of 5 stars	$30.47 +4.3%	$30.27 -0.7%	+189.9%	$2.01B	N/A	N/A	32

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OVID) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ovid Therapeutics (OVID) Competitors

OVID vs. LKFT, PGEN, SNDX, BCAX, and SION

How does Ovid Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Ovid Therapeutics compare to Precigen?

Summary

How does Ovid Therapeutics compare to Syndax Pharmaceuticals?

Summary

How does Ovid Therapeutics compare to Bicara Therapeutics?

Summary

How does Ovid Therapeutics compare to Sionna Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ovid Therapeutics (OVID) Competitors

OVID vs. LKFT, PGEN, SNDX, BCAX, and SION

How does Ovid Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Which has better valuation & earnings, LKFT or OVID?

Which has more volatility & risk, LKFT or OVID?

Do insiders and institutionals hold more shares of LKFT or OVID?

Does the media prefer LKFT or OVID?

Do analysts recommend LKFT or OVID?

Is LKFT or OVID more profitable?

Summary

How does Ovid Therapeutics compare to Precigen?

Which has more volatility and risk, OVID or PGEN?

Which has stronger valuation & earnings, OVID or PGEN?

Do institutionals and insiders have more ownership in OVID or PGEN?

Does the media refer more to OVID or PGEN?

Is OVID or PGEN more profitable?

Do analysts rate OVID or PGEN?

Summary

How does Ovid Therapeutics compare to Syndax Pharmaceuticals?

Does the media refer more to OVID or SNDX?

Is OVID or SNDX more profitable?

Which has more risk and volatility, OVID or SNDX?

Which has preferable earnings and valuation, OVID or SNDX?

Do institutionals and insiders believe in OVID or SNDX?

Do analysts rate OVID or SNDX?

Summary

How does Ovid Therapeutics compare to Bicara Therapeutics?

Is OVID or BCAX more profitable?

Do analysts recommend OVID or BCAX?

Do institutionals and insiders believe in OVID or BCAX?

Which has more risk and volatility, OVID or BCAX?

Which has stronger earnings and valuation, OVID or BCAX?

Does the media favor OVID or BCAX?

Summary

How does Ovid Therapeutics compare to Sionna Therapeutics?

Does the media favor OVID or SION?

Do insiders & institutionals believe in OVID or SION?

Which has stronger earnings & valuation, OVID or SION?

Is OVID or SION more profitable?

Which has more risk and volatility, OVID or SION?

Do analysts rate OVID or SION?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools